KRAS and pancreatic adenocarcinoma: Similar observations were made using nanoparticle-formulated Bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES, another GLS1 inhibitor) and metformin in pancreatic adenocarcinoma54, in which K-Ras is frequently mutated; however, the putative role of cyclin D1 in driving this metabolic vulnerability in pancreatic adenocarcinoma cannot be neglected.